Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 376,195 shares of the biopharmaceutical company’s stock after selling 71,892 shares during the quarter. Principal Financial Group Inc. owned 0.30% of Halozyme Therapeutics worth $17,986,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $29,000. Farther Finance Advisors LLC lifted its holdings in Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,028 shares during the last quarter. Centaurus Financial Inc. acquired a new position in Halozyme Therapeutics in the third quarter valued at approximately $127,000. Quantbot Technologies LP acquired a new position in Halozyme Therapeutics in the third quarter valued at approximately $150,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Halozyme Therapeutics during the third quarter valued at approximately $163,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 1.3 %

HALO stock opened at $58.50 on Tuesday. The firm’s 50-day moving average is $53.67 and its two-hundred day moving average is $54.67. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company has a market capitalization of $7.20 billion, a price-to-earnings ratio of 17.06, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Benchmark reissued a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.